Advertisement

Monoclonal Antibody Purged Autologous Bone Marrow Transplantation for Relapsed Non T-Cell Acute Lymphoblastic Leukemia

  • Tak Takvorian
  • Stephen Sallan
  • Jerome Ritz
Part of the Developments in Oncology book series (DION, volume 45)

Abstract

CALLA, the common acute lymphoblastic leukemia antigen, is a 100 kilodalton cell surface glycoprotein which is expressed on approximately 80% of leukemic cells from patients with non T-cell acute lymphoblastic leukemia and 40% of patients with chronic myelogenous leukemia in blast crisis (1,2). In addition, CALLA is expressed by tumor cells from most patients with nodular poorly differentiated lymphocytic lymphoma and Burkitt’s lymphoma, and approximately 40% of T-cell lymphoblastic lymphoma (3). In normal bone marrow, approximately 1% of mononuclear cells express CALLA, but regenerating and fetal marrow express a slightly higher percentage. CALLA is also expressed by other tissues including terminally differentiated granulocytes, renal glomerular cells, cells of the proximal renal tubule and cultured fibroblasts, making the in vivo use of the monoclonal antibody directed against CALLA less effective or dangerous as compared to the in vitro treatment of bone marrow. The monoclonal antibody directed against CALLA is termed J5, is of the murine IgG2A class, and identifies a subset of patients with a relatively good prognosis as compared to non T-cell ALL patients who do not bear CALLA antigen on the surface of their leukemia cells.

Keywords

Acute Lymphoblastic Leukemia Allogeneic Bone Marrow Transplantation Autologous Bone Marrow Transplantation Ablative Regimen Rabbit Complement 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Ritz J, Pesando JM, Notis-McConarty J, Lazarus H and Schlossman SF: A monoclonal antibody to human acute lymphoblastic leukemia antigen. Nature 283:583–585, 1980.PubMedCrossRefGoogle Scholar
  2. 2.
    Greaves MF, Hariri G, Newman RA, Sutherland DR, Ritter MA and Ritz J: Selective expression of the common acute lymphoblastic leukemia (gp100) antigen on immature lymphoid cells and their malignant counterparts. Blood 61:628–639, 1983.PubMedGoogle Scholar
  3. 3.
    Ritz J, Nadler LM, Bhan AK, Notis-McConarty J, Pesando JM and Schlossman SF: Expression of common acute lymphoblastic leukemia antigen (CALLA) by lymphomas of B and T cell lineage. Blood 58:648–652, 1981.PubMedGoogle Scholar
  4. 4.
    Hercend T, Nadler LM, Pesando JM, Reinherz EL, Schlossman SF and Ritz J: Expression of a 26,000 dalton glycoprotein on activated human T cells. Cellular Immunology 64:192–199, 1981.PubMedCrossRefGoogle Scholar
  5. 5.
    Bast RC, Ritz J, Lipton JM, Feeney M, Sallan SE, Nathan DG and Schlossman SF: Elimination of leukemic cells from human bone marrow using monoclonal antibody and complement. Cancer Research 43:1389–1394, 1983.PubMedGoogle Scholar
  6. 6.
    Bast Rc, DeFabritiis P, Lipton JM, Gelber R, Maver C, Nadler L, Sallan S and Ritz J: Elimination of malignant clonogenic cells from human bone marrow using multiple monoclonal antibodies and complement. Cancer Research 45:499–503, 1985.PubMedGoogle Scholar
  7. 7.
    Nadler LM, Stashenko, P, Hardy R, Kaplan WD, Button LN, Kufe DW, Antman KH, and Schlossman SF: Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma associated antigen. Cancer Research 40:3147–3154, 1980.PubMedGoogle Scholar
  8. 8.
    Dillman RO, Shawler DL, Sobol RE, Collins HA, Beauregard JC, Wormsley SB and Royston I: Murine monoclonal antibody therapy in two patients with chronic lymphocytic leukemia. Blood 59:1036–1045, 1982.PubMedGoogle Scholar
  9. 9.
    Miller RA, Maloney DA, Warnke R and Levy R: Treatment of a B cell lymphoma with monoclonal anti-idiotype antibody. New England Journal of Medicine 306:517–522, 1982.PubMedCrossRefGoogle Scholar
  10. 10.
    Miller RA, Oseroff AR, Stratte PT and Levy R: Monoclonal antibody therapeutic trials in seven patients with T cell lymphoma. Blood 62:988–995, 1983.PubMedGoogle Scholar
  11. 11.
    Ritz J and Schlossman SF: Utilization of monoclonal antibodies in the treatment of leukemia and lymphoma. Blood 59:1–11, 1982.PubMedGoogle Scholar
  12. 12.
    Ritz J, Pesando JM, Sallan SE, Clavell LA, Notis-McConarty J, Rosenthal P and Schlossman SF: Serotherapy of acute lymphoblastic leukemia with monoclonal antibody. Blood 58:141–152, 1981.PubMedGoogle Scholar
  13. 13.
    Johnson FL, Thomas ED, Clark BS, Chard RL, Harmann JR and Storb R: A comparison of marrow transplantation with chemotherapy for children with acute lymphoblastic leukemia in second or subsequent remission. New England Journal of Medicine 305:846–851, 1981.PubMedCrossRefGoogle Scholar
  14. 14.
    Thomas ED, Sanders JE, Flournoy N, Johnson FL, Buckner CD, Clift RA, Fefer A, Goodell BW, Storb R and Wreiden PL: Marrow transplantation for patients with acute lymphoblastic leukemia: A long-term follow-up. Blood 62:1139–1141, 1983.PubMedGoogle Scholar
  15. 15.
    Gale RP, Kersey JH, Bortin MM, Dicke KA, Good RA, Zwaan FE and Rimm AA: Bone Marrow for acute lymphoblastic leukemia. Lancet 2:663–667, 1983.PubMedGoogle Scholar
  16. 16.
    Sharkis SJ, Santos GW and Colvin M: Elimination of acute myelogenous leukemic cells from marrow and tumor suspensions in the rat with 4-hydroperoxycyclophosphamide. Blood 55:521–523, 1980.PubMedGoogle Scholar
  17. 17.
    DeFabritiis P, Bregni M, Lipton J, Greenberger J, Nadler L, Rothstein L, Korbling M, Ritz J and Bast RC Jr: Elimination of clonogenic Burkitt’s lymphoma cells from human bone marrow using 4-hydroperoxycyclophosphamide in combination with monoclonal antibodies and complement. Blood 65:1064–1070, 1985.Google Scholar

Copyright information

© Martinus Nijhoff Publishers, Dordrecht 1986

Authors and Affiliations

  • Tak Takvorian
    • 1
  • Stephen Sallan
    • 1
  • Jerome Ritz
    • 1
  1. 1.Division of Medical Oncology, Pediatric Oncology, and Tumor ImmunologyDana-Farber Cancer InstituteBostonUSA

Personalised recommendations